Partners In Health

• A phase 3 clinical trial, endTB, has identified three new 9-month, all-oral drug regimens as effective alternatives to the standard 18-24 month treatment for rifampin-resistant tuberculosis. • The new regimens, combining drugs like bedaquiline and delamanid, demonstrated favorable outcomes in 85% to 90% of participants, comparable to the 81% success rate of the control group. • These shorter, less toxic regimens have been endorsed by the WHO and offer improved accessibility and affordability, with some costing less than $500, potentially transforming TB treatment. • The study included diverse populations, such as children, pregnant women, and individuals with HIV or hepatitis C, often excluded from clinical trials, making the findings broadly applicable.

Partners In Health

Shorter, All-Oral Regimens Show Promise for Rifampin-Resistant Tuberculosis